Pricing Log in Create free account
Friday 6 November 2026 Export CDNA’s income statement to Excel — free account

CareDx, Inc.

CDNA Healthcare Diagnostics & Research

CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.

Revenue
+39.3%
EPS
+1,133.3%
Free cash flow
−68.6%

Quarter to September 2026, against a year earlier

76.96 8.90 −10.37%
Market cap
$4.0B
P/E
30.9×
Fwd P/E
36.2×
Dividend yield
—
F-score
5/9
Altman Z
4.14
Beneish M
−3.36
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 13.27
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 2 1 — 1 2 5 2 4 — — —
Insider Ownership 8.22%

Capital & Financial Ratios $m

Size
Market Cap 4,010.00
Revenue ttm 497.40
Net income ttm 128.63
Free cash flow ttm 59.76
Net debt Q (250.48)
Valuation
P/E 30.91
Forward P/E 36.20 (above 35: high)
Price / sales 8.06
Forward P/S Powerpack
Price / FCF 68.93
Price / book 8.58 (above 6: high)
Financial health
Current ratio Q 2.31 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (9.08)
Growth
Revenue growth Q +39.29% (above 0%: growing)
Operating income growth Q +3,397.56% (above 0%: growing)
EPS, this year +207.18% (at or above 15%: strong)
EPS, next year A −11.41% (below 0%: weak)
Revenue, next year A +35.57% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +55.24% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 7.6×, against a ten-year median of 3.0×; over the ten years it ranged from 0.1× in 2023 to 18.1× in 2018.
P/S against its own 10 years 71.36%
10-year low 10-year high
P/B against its own 10 years 72.99%
10-year low 10-year high
EV/Sales against its own 10 years 71.17%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 235 261 177 250
Receivables 51 65 43 48
Inventory 19 20 27 9
Other — — — —
314 352 257 321
2023 2024 2025 Q'26
Payables 13 8 10 11
ST’ Debt — — — —
Other — — — —
78 89 90 139

Compound Annual Growth %

10y 5y 3y
Sales 29.72% 14.59% 5.68%
Cash Flow 0.00% 4.69% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 26.24% 1.77% (11.07%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.24 Actual 0.70

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.24 0.12 Miss by 0.12
Q1 FY26 0.11 0.34 Beat by 0.23
Q2 FY26 0.22 0.37 Beat by 0.15
Q3 FY26 0.24 0.70 Beat by 0.46
Q4 FY26 0.24 — Reports 23 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.05 2.07 0.35 — —
’25 (0.19) (0.16) 0.03 (0.08) (0.40)
’24 (0.38) (0.09) (0.20) 1.51 0.93
’23 (0.44) (0.46) (0.43) (2.21) (3.54)
’22 (0.37) (0.41) (0.32) (0.34) (1.44)
’21 (0.01) (0.04) (0.23) (0.31) (0.59)
’20 (0.14) (0.15) (0.06) (0.07) (0.40)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 118 132 139 — —
’25 85 87 100 108 380
’24 72 92 83 87 334
’23 77 70 67 66 280
’22 79 81 79 82 322
’21 67 74 76 79 296
’20 38 42 53 59 192
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 4 31 13 — —
’25 (27) 10 37 21 42
’24 (15) 19 13 22 38
’23 1 0 (10) (8) (18)
’22 (21) (4) (7) 7 (25)
’21 (34) 10 0 4 (19)
’20 (3) 24 5 7 33
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 1 29 11 — —
’25 (28) 9 35 19 35
’24 (17) 17 11 20 32
’23 (2) (3) (13) (10) (28)
’22 (30) (11) (13) 4 (50)
’21 (36) 1 (3) (2) (40)
’20 (5) 20 1 7 23
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 41 48 77 127 192 296 322 280 334 380 497 +28.2% 515 555 608 +16.9%
Gross margin, % 48.02 55.78 56.92 64.23 67.16 67.14 65.13 63.59 67.14 67.55 70.97 +19.5 pt
EBT (41) (57) (48) (24) (20) (32) (76) (190) 53 (21) 124 (7.2%)
EBT margin, % (101.80) (118.51) (62.97) (18.85) (10.28) (10.83) (23.69) (67.83) 15.84 (5.55) 24.97 +96.3 pt
Net income (40) (56) (47) (22) (19) (31) (77) (190) 53 (21) 129 (6.7%)
Per share, $
Per share, $ Revenue 2.46 2.07 2.15 3.01 4.13 5.67 6.03 5.21 6.32 7.13 9.54 +12.5%
Earnings (2.39) (2.38) (1.31) (0.52) (0.40) (0.59) (1.44) (3.54) 1.00 (0.40) 2.49 (18.0%)
Cash flow (1.00) (0.61) (0.11) (0.07) 0.72 (0.37) (0.47) (0.34) 0.72 0.79 1.32 n/m
Capex (0.03) (0.01) (0.20) (0.08) (0.22) (0.39) (0.46) (0.17) (0.12) (0.12) (0.18) +15.7%
Free cash flow (1.03) (0.62) (0.32) (0.15) 0.50 (0.76) (0.93) (0.51) 0.60 0.67 1.15 n/m
Book value 1.20 (0.26) 2.69 2.35 5.97 8.92 8.08 4.86 7.17 5.69 8.97 +18.9%
Shares, m 16 23 36 42 46 52 53 54 53 53 52 +13.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.53 0.00 30.91 2.3
P/S 0.93 3.40 11.70 7.16 17.52 8.02 1.84 2.29 3.39 2.64 8.06 5.9
P/B 1.92 0.00 9.34 9.18 12.13 5.10 1.37 2.46 2.99 3.31 8.58 4.8
EV/Sales 1.10 3.76 11.04 6.86 16.44 6.85 0.94 1.46 2.61 2.18 7.57 5.3
EV/FCF (2.61) (12.53) (139.89) (120.34) 144.12 (51.32) (6.08) (14.29) 29.38 24.00 64.67 (15.0)
Cash, $m
Cash, $m Operating cash flow (17) (14) (4) (3) 33 (19) (25) (18) 38 42 69 n/m
Capex (1) 0 (7) (3) (10) (20) (24) (9) (6) (7) (9) +31.8%
Free cash flow (17) (14) (11) (6) 23 (40) (50) (28) 32 35 60 n/m
Balance, $m
Balance, $m Working capital (14) (16) 62 37 204 356 312 236 262 167 182 n/m
Net debt 7 17 (65) (38) (225) (348) (293) (235) (261) (177) (250) n/m
Shareholders’ equity 20 (6) 96 99 278 466 431 261 378 303 467 +35.4%
Returns, %
Returns, % ROA (59.64) (69.21) (43.64) (15.56) (7.19) (6.56) (13.81) (37.69) 10.97 (4.72) 23.96 +54.9 pt
ROIC (88.22) (113.15) (31.09) (25.23) (26.58) (15.83) (35.02) (490.55) 21.63 (15.28) 33.56 +72.9 pt
ROE (160.26) (803.49) (103.93) (22.54) (9.94) (8.25) (17.09) (54.98) 16.43 (6.27) 33.04 +154.0 pt
People
People Employees 161 179 231 386 475 645 738 643 650 765 — +18.9%
Revenue/emp, $m 0.25 0.27 0.33 0.33 0.40 0.46 0.44 0.44 0.51 0.50 — +7.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

CareDx, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RDNT RadNet, Inc. $6.1B — (loss-making) 1,050× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34% Compare
GRAL GRAIL, Inc. $5.3B — (loss-making) — (loss-making) +3.71% (above 0%: growing) n/m −24.90% (below 0%: shrinking) 0.00% (385.29%) Compare
BLLN BillionToOne, Inc. $5.3B 88.7× 146× +47.24% (above 0%: growing) +164.29% (above 0%: growing) +9.25% (above 0%: growing) 70.86% 8.96% Compare
SHC Sotera Health Company $4.5B 26.3× 26.4× +4.36% (above 0%: growing) +20.12% (above 0%: growing) +64.98% (above 0%: growing) 55.65% 34.98% Compare
ADPT Adaptive Biotechnologies Corporation $4.3B — (loss-making) — (loss-making) −10.72% (below 0%: shrinking) −66.67% (below 0%: shrinking) +201.86% (above 0%: growing) 76.24% (0.54%) Compare
CDNA CareDx, Inc. $4.0B 30.9× 36.2× +39.29% (above 0%: growing) +1,133.33% (above 0%: growing) −68.62% (below 0%: shrinking) 71.09% 5.82%
NEO NeoGenomics, Inc. $2.1B — (loss-making) — (loss-making) +11.43% (above 0%: growing) n/m −3,724.21% (below 0%: shrinking) 46.16% (3.79%) Compare
VCYT Veracyte, Inc. $1.9B 15.2× 45.2× +15.08% (above 0%: growing) +62.50% (above 0%: growing) −9.63% (below 0%: shrinking) 70.58% 10.92% Compare
WGS GeneDx Holdings Corp. $1.9B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
Median of peers $4.4B 26.3× 95.6× +11.44% +20.12% −17.26% 62.01% 2.90%

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 27 April 2026

Ownership

Directors and executive officers, together 2.40%
BlackRock, Inc. 8.60%
Baron Capital Group 6.20%
Bellevue Group AG. 6.10%
Neil Gagnon 6.00%
State Street Corporation 5.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

CareDx, Inc. (CDNA) Latest News

3 Nov

Impact 4 · · Zacks

30 Oct

Impact 4 · · Moby
Impact 3 · · The Motley Fool
Impact 3 · · The Motley Fool transcript

29 Oct

Impact 4 · · MarketBeat
Impact 4 · · Zacks
Impact 4 · · Business Wire
Impact 3 · · Associated Press

27 Oct

Impact 4 · · Simply Wall St.

26 Oct

Impact 4 · · Zacks

22 Oct

Impact 4 · · Business Wire

9 Oct

Impact 4 · · Simply Wall St.

25 Sep

Impact 4 ·

24 Sep

Impact 4 · · TIKR

31 Jul

Impact 3 · · The Motley Fool
Impact 3 ·

30 Jul

Impact 4 · · MarketBeat
Impact 3 ·
Impact 3 ·

23 Jul

Impact 3 ·

18 Jul

Impact 4 ·
Impact 4 ·
Impact 3 ·

16 Jul

Impact 4 · · InvestorsHub
Impact 4 ·

7 Jul

Impact 4 ·

2 Jul

Impact 4 ·

1 Jul

Impact 4 ·
Impact 4 ·

30 Jun

Impact 3 ·

CDNA metrics, ten years each

stockrow.com/CDNA · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com